buy ghd hair Topfond Pharmaceutical - additional p

43nike9485qt

train collector html simple template model

Topfond Pharmaceutical: additional projects to improve the industrial chain
- Yahoo Finance

Additional parties to develop new business-day Pharmaceutical (600253) The issuance of the project includes four kinds of raw materials, drugs, respectively, of 10,000 tons of vitamin B3,[link widoczny dla zalogowanych], 1000 tons of vitamin K3, 500 吨 cefprozil and 300 tons to a fund adriamycin. In addition to the issuance of additional profit growth for the company, but also give full consideration to the Group's future development plans. Company as the strongest industrial entities within the Group, the raw material drug production technologies have obvious advantages, the company has also been identified as the raw material medicine production base within the Group, namely through the improvement of internal industry chain, to achieve synergies. On specific products, the main provider of cefprozil give cephalosporin bulk drugs for the expertise of the general sales agents Sanyo, vitamin B3 and vitamin K3 are mainly involved in nutrition and health products business groups reserve the API. Additional plans in this release, while an open, common-day Party Group also acquired 90 million yuan through the accounts receivable ways to improve the quality of its assets and cash flow position. We believe that this acquisition is part of the support group to the company, the future for the protection of issuance and the successful completion of implementation of the project, the group will also give more support. On the other hand,[link widoczny dla zalogowanych], General Technology Group stationed day side in 2008 when the promised investment in 3-5 years, 3.0 billion to help the development of common-day side. With the issuance and investment of 5 billion dollars in cash before, the group has invested less than 10 billion yuan. Follow-up to 2 billion yuan of investment leave room for imagination. Before additional promising technology leader, the company has already conducted a number of small scale production technology and pilot to explore, so technology is already quite mature. Specific varieties, the vitamin B3 and vitamin K3 is a technical cooperation project with external technical support. API for cefprozil, the company already has received in 2005 the production of cefprozil API approval, and hold a mature production technology. According to the present progress, we expect the second half of this year will be formally launched. Feasibility report in accordance with the design schedule, the project will contribute to profits in 2011. Vitamin B3, also called nicotinic acid, in the feed, food and medicine is widely used. According to China National Chemical Information Center, the largest domestic manufacturer Lonza Guangzhou Fine Chemicals, and its production capacity has reached 14,[link widoczny dla zalogowanych],500 tons. Vitamin B3 companies involved in the dare program, mainly through technical cooperation to the company access to new technology synthetic vitamin B3 - catalytic hydration. Lonza Fine Chemicals and other technology used in different catalytic hydration a biological catalyst, lower cost, less pollution. Foreseeable future, Vitamin B3 industry will be the same place with the pan-industry changes in calcium, the day side medicine is undoubtedly the industry's technology leader. Preparation is still the direction of the company in 2009 the income of drug substances and drug 2.5:1, respectively. The company's future development goals is to increase the proportion of revenue agents, so that the ratio of drug substance and drug reaches 1:1. Generic drugs for preparations for the main problem of low margins, the company will focus on new drug development area. The company has received more than 3 class of 11 new drug formulations production approval, in the assessment phase of the three. Then there are other potential generic species such as atorvastatin calcium capsules, risedronate sodium tablets, finasteride tablets, telmisartan tablets. Kinds of raw materials to pharmaceutical companies lincomycin-based, the current production capacity has reached 1,300 tons / year in 2009, lincomycin production of about 1,000 tons, revenue income of about 46% of the API. Nanyang Pukang from normal production because of environmental problems can not be since the price of lincomycin remained at 380 / bou highs. Taking into account environmental issues governance is difficult, so we can expect the price of lincomycin remain high. Higher prices because of the recent erythromycin thiocyanate,[link widoczny dla zalogowanych], the company also made in the production adjustment, the current production capacity has reached the red sulfur 12 tons / month. Earnings forecasts and investment ratings carried out in accordance with the progress of the project, we expect the project to the company the fastest impact on 2011 results. Because of atorvastatin calcium is still in the early marketing, future growth is not there some uncertainty, was considered prudent that we cut this part of revenues is expected 2010-2012 atorvastatin calcium capsules income for 50 million yuan, 100 million yuan and 15,000 yuan. Click here to assume earnings per share estimates for 2010-2012 were 0.19 yuan, 0.27 yuan and 0.36 yuan, currently valued at a high price-earnings ratio, but taking into account the performance of the company is rapidly improving, or at a later stage to give more support groups, we maintain the company a \
More articles related to topics：

discount cosmetics mac 244 IPOs this year, the fir

[link widoczny dla zalogowanych]

mac cosmetics wholesale Hongrun Construction the r